MAP2K7 and metastatic melanoma: This was blocked by adding the MEK inhibitor trametinib, allowing for sustained therapy and more durable responses [3]. Both immunotherapy and dual oral targeted therapy have also been shown to improve the cure rate in higher-risk non-metastatic melanoma, specifically Stage 2B and 3 for immunotherapy and Stage 3 for targeted therapy if a B-raf mutation is present, as reviewed by Luke et al. [5].